Cantor Sees Possible Acquisitions For Valeant Pharmaceuticals in 2015


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


Cantor Fitzgerald analyst Daniel Brims commented Tuesday that Valeant Pharmaceuticals Intl Inc. (NYSE: VRX) may make dental acquisitions in 2015. Brims maintained a Buy rating on the company.

Possible targets based valuation, cost synergies and business overlap include Align Technology, Inc. (NASDAQ: ALGN), DENTSPLY International Inc. (NASDAQ: XRAY) Henry Schein, Inc. (NASDAQ: HSIC) and Patterson Companies, Inc. (NASDAQ: PDCO).

The above names were quiet in Tuesday’s trading session despite the analyst’s comments.

Valeant Pharmaceuticals Intl Inc. recently traded at $143.33, up 1.03 percent.
 


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst ColorAnalyst RatingsCantor FitzgeraldDaniel Brims